Harary arrives at a critical juncture for the New York-based startup, which seeks to standardize a new drug category combining conventional prescriptions with personalized behavioral and cognitive software. His two-decade career includes senior leadership roles at Teva, where he directed R&D in neuroscience and immunology, contributing to the development of therapies like UZEDY and AUSTEDO. He also brings extensive experience in implementing machine learning and big data strategies within drug development lifecycles.

Co-CEOs Michal Tsur and Or Shoval noted that Harary’s expertise in both early and late-stage development aligns with the company’s goal to transition its Hybridopa program into global Phase III testing by the fourth quarter of 2026. For his part, Harary emphasized the potential of non-pharmaceutical interventions to amplify molecular therapeutic effects. He intends to leverage the current regulatory climate to scale Remepy’s model, which aims to turn standard medications into adaptive, software-enabled treatment platforms.